ALYSSA LOFTUS: Open Payments
NPI 1346894623 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,041 in 44 payments from 14 companies in 2025. Trend: 2023 $1,047 · 2024 $1,041 · 2025 $1,041
Food & beverage: $1,041
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $160 |
| Alkermes, Inc. | 6 | $136 |
| Neurocrine BioSciences, Inc. | 5 | $120 |
| E.R. Squibb & Sons, L.L.C. | 4 | $117 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Lundbeck LLC | 3 | $83 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Axsome Therapeutics, Inc. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Corium, LLC | 3 | $48 |
Products named: REXULTI, CAPLYTA, INGREZZA, COBENFY, LYBALVI, Auvelity, ARISTADA, Azstarys.
Industry payments across PA — which companies pay providers there.
